Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 17, 2016 - Issue 3
Submit an article Journal homepage
918
Views
14
CrossRef citations to date
0
Altmetric
Reviews

Drugs for the treatment of peripheral neuropathies

Paola MarmiroliExperimental Neurology Unit, School of Medicine and Surgery and Milan Center for Neuroscience, University of Milano-Bicocca, Monza, Italy
&
Guido CavalettiExperimental Neurology Unit, School of Medicine and Surgery and Milan Center for Neuroscience, University of Milano-Bicocca, Monza, ItalyCorrespondence[email protected]
Pages 381-394 | Received 17 Oct 2015, Accepted 12 Nov 2015, Published online: 05 Dec 2015

References

  • Papers of special note have been highlighted as either “of interest” (•) or “of considerable interest” (••) to readers.
  • Italian General Practitioner Study Group (IGPSG). Chronic symmetric symptomatic polyneuropathy in the elderly: a field screening investigation in two Italian regions. I. Prevalence and general characteristics of the sample. Neurology. 1995;45(10):1832–1836.
  • Ueda M, Ando Y. Recent advances in transthyretin amyloidosis therapy. Transl Neurodegener. 2014;3:19.
  • Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol. 2005;62(7):1057–1062.
  • Adams D, Lozeron P, Lacroix C. Amyloid neuropathies. Curr Opin Neurol. 2012;25(5):564–572.
  • Lai Z, Colón W, Kelly JW. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry. 1996;35(20):6470–6482.
  • Adams D, Cauquil C, Theaudin M, et al. Current and future treatment of amyloid neuropathies. Expert Rev Neurother. 2014;14(12):1437–1451.

• Extensive review of the pathogenesis of FAP, previous therapeutic trials and future developments of the pharmacological and non-pharmacological treatments.

•• Guidelines for the clinical management from diagnosis to treatment of FAP.

  • Stangou AJ, Hawkins PN. Liver transplantation in transthyretin-related familial amyloid polyneuropathy. Curr Opin Neurol. 2004;17(5):615–620.
  • Wilczek HE, Larsson M, Ericzon BG, et al. Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR). Amyloid. 2011;18(Suppl 1):193–195.
  • Ackermann EJ, Guo S, Booten S, et al. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid. 2012;19(Suppl 1):43–44.
  • Coelho T, Maia LF, da Silva AM, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013;260(11):2802–2814.
  • Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785–792.
  • Lozeron P, Théaudin M, Mincheva Z, et al. Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol. 2013;20(12):1539–1545.
  • Merlini G, Planté-Bordeneuve V, et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res. 2013;6(6):1011–1020.
  • Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310(24):2658–2667.
  • Benson MD, Kluve-Beckerman B, Zeldenrust SR, et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve. 2006;33(5):609–618.
  • Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369(9):819–829.
  • Bodin K, Ellmerich S, Kahan MC, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature. 2010;468(7320):93–97.
  • Hughes R, Swan A, Cornblath D, et al. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Lancet. 1997;349(9047):225–230.

• Large randomized, controlled trial directly comparing plasma exchange, intravenous immunoglobulins or the sequential use of the two treatments in patiens with Guillain-Barre syndrome unable to walk unassisted.

  • Raphaël JC, Chevret S, Hughes RA, et al. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2012;7:CD001798.
  • Berger M, Allen JA. Optimizing IgG therapy in chronic autoimmune neuropathies: a hypothesis driven approach. Muscle Nerve. 2015;51(3):315–326.
  • Hughes RA, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2012;8:CD001446.
  • Halstead SK, Zitman FM, Humphreys PD, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain. 2008;131(Pt 5):1197–1208.
  • Kleyman I, Brannagan TH. Treatment of chronic inflammatory demyelinating polyneuropathy. Curr Neurol Neurosci Rep. 2015;15(7):47.
  • Mehndiratta MM, Hughes RA, Pritchard J. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2015;8:CD003906.
  • Van den Bergh PY, Hadden RD, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – first revision. Eur J Neurol. 2010;17(3):356–363.

•• Guidelines produced by a highly representative group of experts in oder to update the clinical suggestions in the management of chronic inflammatory demyelinating polyradiculoneuropathy.

  • Eftimov F, Winer JB, Vermeulen M, et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2009;1:CD001797.

• Systematic review assessing the different studies indicating the efficacy of intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.

  • Nobile-Orazio E, Cocito D, Jann S, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol. 2012;11(6):493–502.
  • Imbach P, Barandun S, d’Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1(8232):1228–1231.
  • Berger M, Rojavin M, Kiessling P, et al. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol. 2011;139(2):133–141.
  • Berger M, Jolles S, Orange JS, et al. Bioavailability of IgG administered by the subcutaneous route. J Clin Immunol. 2013;33(5):984–990.
  • Hughes RA, Mehndiratta MM. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2015;1:CD002062.

• Systematic review assessing the different studies indicating the efficacy of corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy.

  • Nobile-Orazio E, Cocito D, Jann S, et al. Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP. J Neurol Neurosurg Psychiatry. 2015;86(7):729–734.
  • Robert F, Edan G, Nicolas G, et al. A retrospective study on the efficacy and safety of intraveinous immunoglobulin (Tegeline(®)) in patients with chronic inflammatory demyelinating polyneuropathy. Presse Med. 2015;44(7–8):e291–e300.
  • Cocito D, Paolasso I, Antonini G, et al. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2010;17(2):289–294.
  • Koski CL. Treatment of multifocal motor neuropathy with intravenous immunoglobulin. J Clin Immunol. 2014;34(Suppl 1):S127–S131.
  • Hadden RD, Marreno F. Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction. Ther Adv Neurol Disord. 2015;8(1):14–19.

••The paper provides very important information allowing a more safe decision when switch from intravenous to subcutaneous immunoglobulin is recommended.

  • Yoon MS, Gold R, Kerasnoudis A. Subcutaneous immunoglobulin in treating inflammatory neuromuscular disorders. Ther Adv Neurol Disord. 2015;8(4):153–159.
  • van Schaik IN, Bouche P, Illa I, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Eur J Neurol. 2006;13(8):802–808.

••Guidelines produced by a highly representative group of experts in oder to update the clinical suggestions in the management of multifocal motor neuropathy.

  • Chaudhry V, Corse AM, Cornblath DR, et al. Multifocal motor neuropathy: response to human immune globulin. Ann Neurol. 1993;33(3):237–242.
  • Raheja D, Specht C, Simmons Z. Paraproteinemic neuropathies. Muscle Nerve. 2015;51(1):1–13.
  • Carpo M, Meucci N, Allaria S, et al. Anti-sulfatide IgM antibodies in peripheral neuropathy. J Neurol Sci. 2000;176(2):144–150.
  • Nobile-Orazio E, Baldini L, Barbieri S, et al. Treatment of patients with neuropathy and anti-MAG IgM M-proteins. Ann Neurol. 1988;24(1):93–97.
  • Nobile-Orazio E, Manfredini E, Carpo M, et al. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol. 1994;36(3):416–424.
  • Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev. 2012;5:CD002827.

• Systematic review assessing the different studies indicating the efficacy of corticosteroids for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.

  • Dispenzieri A. POEMS syndrome: Update on diagnosis, risk-stratification, and management. Am J Hematol. 2015;90(10):951–962.
  • Li J, Zhou DB. New advances in the diagnosis and treatment of POEMS syndrome. Br J Haematol. 2013;161(3):303–315.
  • Kuwabara S, Dispenzieri A, Arimura K, et al. Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. Cochrane Database Syst Rev. 2012;6:CD006828.

• Systematic review assessing the different studies indicating the efficacy of corticosteroids for POEMS.

  • Dispenzieri A, Gertz MA. Treatment of POEMS syndrome. Curr Treat Options Oncol. 2004;5(3):249–257.
  • Moulik PK, Mtonga R, Gill GV. Amputation and mortality in new-onset diabetic foot ulcers stratified by etiology. Diabetes Care. 2003;26(2):491–494.
  • Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28(4):956–962.
  • Abbott CA, Malik RA, van Ross ER, et al. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care. 2011;34(10):2220–2224.
  • Ziegler D, Rathmann W, Dickhaus T, et al. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med. 2009;10(2):393–400.
  • Tesfaye S, Stevens LK, Stephenson JM, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM complications study. Diabetologia. 1996;39(11):1377–1384.
  • Javed S, Petropoulos IN, Alam U, et al. Treatment of painful diabetic neuropathy. Ther Adv Chronic Dis. 2015;6(1):15–28.

• The paper provides a comprehensive and accurate update of the large number of clinical trials perofmed in symptomatic diabetic neuropathy and it also describes the possible future developments in this field.

••This paper represents a careful revision of the current knowledge not only in synptomatic treatment of diabetic neuropathy, but also on the possible future of causal treatments.

  • Sun M, Zhang M, Shen J, et al. Critical appraisal of international guidelines for the management of diabetic neuropathy: is there global agreement in the internet era? Int J Endocrinol. 2015;2015:519032.

•• This review highlights the need for a more homogeneous design for practical guidelines in the treatment of painful diabetic neuropathy although the comments might easily be extended to other painful conditions.

  • The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–986.
  • Callaghan BC, Little AA, Feldman EL, et al. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012;6:CD007543.
  • Fullerton B, Jeitler K, Seitz M, et al. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2014;2:CD009122.
  • Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011;343:d4169.
  • Snedecor SJ, Sudharshan L, Cappelleri JC, et al. Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract. 2014;14(2):167–184.
  • Pop-Busui R, Stevens MJ, Raffel DM, et al. Effects of triple antioxidant therapy on measures of cardiovascular autonomic neuropathy and on myocardial blood flow in type 1 diabetes: a randomised controlled trial. Diabetologia. 2013;56(8):1835–1844.
  • Papanas N, Ziegler D. Efficacy of α-lipoic acid in diabetic neuropathy. Expert Opin Pharmacother. 2014;15(18):2721–2731.
  • Ziegler D, Movsesyan L, Mankovsky B, et al. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care. 2009;32(8):1479–1484.
  • Ekberg K, Brismar T, Johansson BL, et al. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care. 2007;30(1):71–76.
  • Ekberg K, Johansson BL. Effect of C-peptide on diabetic neuropathy in patients with type 1 diabetes. Exp Diabetes Res. 2008;2008:457912.
  • Ruggenenti P, Lauria G, Iliev IP, et al. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension. 2011;58(5):776–783.
  • Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113–e88.

••Guidelines produced by one of the most representative European Societies grouping neurologists and pain treatment experts, still representing an accepted clinical instrument for daily practice and research.

  • Chou R, Carson S, Chan BK. Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct and indirect meta-analyses of randomized controlled trials. J Gen Intern Med. 2009;24(2):178–188.
  • Quilici S, Chancellor J, Löthgren M, et al. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol. 2009;9:6.
  • Bril V, England J, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011;76(20):1758–1765.

••Guidelines produced by an Amarican task force grouping expert professionals involved in the treatment and care of painful neuropathy in diabetic patients.

  • Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro-Oncology. 2012;14(SUPPL.4):iv45–iv54.

• Extended revision of the current knowledge in chemotherapy-induced peripheral neurotoxicity, with a focus also on “targeted” (biological) therapies, and its care in the different settings.

  • Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941–1967.

••This is the most recent revision of the possible theraputic option to treat chemotherapy-induced peripheral neurotoxicity performed by a task force including American and European oncologists, pain specialists, and neurologist.

  • Albers JW, Chaudhry V, Cavaletti G, et al. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2014;3:CD005228.

• Most updated version of a systematic review assessing the different studies indicating the lack of efficacy of all the treatments tested so far to prevent platinum drug-induced peripheral neurotoxicity.

  • Albers JW, Chaudhry V, Cavaletti G, et al. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2011;2:CD005228.
  • Albers J, Chaudhry V, Cavaletti G, et al. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2007;1:CD005228.
  • Ben-Arye E, Samuels N, Schiff E, et al. Quality-of-life outcomes in patients with gynecologic cancer referred to integrative oncology treatment during chemotherapy. Support Care Cancer. 2015;23(12):3411–3419.
  • Colson K. Treatment-related symptom management in patients with multiple myeloma: a review. Support Care Cancer. 2015;23(5):1431–1445.
  • Ewertz M, Qvortrup C, Eckhoff L. Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Acta Oncol. 2015;54(5):587–591.
  • Mols F, Beijers AJ, Vreugdenhil G, et al. Chemotherapy-induced peripheral neuropathy, physical activity and health-related quality of life among colorectal cancer survivors from the PROFILES registry. J Cancer Surviv. 2015;9(3):512–522.
  • Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol. 2010;6(12):657–666.
  • Argyriou AA, Bruna J, Marmiroli P, et al. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2012;82(1):51–77.
  • Pisano C, Pratesi G, Laccabue D, et al. Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res. 2003;9(15):5756–5767.
  • Avan A, Postma TJ, Ceresa C, et al. Platinum-induced neurotoxicity and preventive strategies: past, present, and future. Oncologist. 2015;20(4):411–432.
  • Amara S. Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy. Ann Pharmacother. 2008;42(10):1481–1485.
  • Schmalbruch H, Krarup C. Animal models of neuropathies. Baillieres Clin Neurol. 1996;5(1):77–105.
  • Carozzi VA, Chiorazzi A, Canta A, et al. Chemotherapy-induced peripheral neurotoxicity in immune-deficient mice: new useful ready-to-use animal models. Exp Neurol. 2015;264:92–102.
  • Marmiroli P, Nicolini G, Miloso M, et al. The fundamental role of morphology in experimental neurotoxicology: the example of chemotherapy-induced peripheral neurotoxicity. Ital J Anat Embryol. 2012;117(2):75–97.
  • Cavaletti G, Nicolini G, Marmiroli P. Neurotoxic effects of antineoplastic drugs: the lesson of pre-clinical studies. Front Biosci. 2008;13:3506–3524.
  • Cavaletti G, Matà S, Fasano A, et al. Lipid-free versus lipid-bound P2 protein-induced experimental allergic neuritis: clinicopathological, neurophysiological, and immunological study. J Neurosci Res. 2000;62(5):709–716.
  • Gewandter JS, Fan L, Magnuson A, et al. Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study. Support Care Cancer. 2013;21(7):2059–2066.
  • Simoneau GG, Ulbrecht JS, Derr JA, et al. Postural instability in patients with diabetic sensory neuropathy. Diabetes Care. 1994;17(12):1411–1421.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.